solid-1029x579.png
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
December 07, 2023 08:00 ET | Solid Biosciences Inc.
– Next-generation gene transfer therapy to treat Duchenne receives FDA Fast Track Designation – CHARLESTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life...
solid-1029x579.png
Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference
November 22, 2023 08:00 ET | Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
solid-1029x579.png
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
November 14, 2023 16:05 ET | Solid Biosciences Inc.
– Planning to initiate Phase 1/2 trial in pediatric DMD Patients –– First cohort to study patients 4 to < 6 years of age –CHARLESTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences...
solid-1029x579.png
Solid Biosciences to Participate at Jefferies London Healthcare Conference
November 09, 2023 08:00 ET | Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
solid-1029x579.png
Solid Biosciences Provides Third Quarter Business Update and Financial Results
November 08, 2023 16:17 ET | Solid Biosciences Inc.
– IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter...
solid-1029x579.png
Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer
October 02, 2023 08:00 ET | Solid Biosciences Inc.
- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid’s focus on both...
solid-1029x579.png
Solid Biosciences to Participate at Upcoming Investor Conferences
September 20, 2023 08:00 ET | Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
solid-1029x579.png
Solid Biosciences to Participate at Upcoming Investor Conferences
September 05, 2023 08:56 ET | Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
solid-1029x579.png
Solid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference
August 31, 2023 08:00 ET | Solid Biosciences Inc.
CHARLESTOWN, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
solid-1029x579.png
Solid Biosciences Provides Second Quarter Business Update and Financial Results
August 14, 2023 16:17 ET | Solid Biosciences Inc.
– On track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) – – Executed licensing agreement for development and...